Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:DRTX
- CUSIP: 26658A10
- Web: N/A
- 200 Day Moving Avg: $24.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.64
- P/E Growth: 0
Frequently Asked Questions for Durata Therapeutics (NASDAQ:DRTX)
What is Durata Therapeutics' stock symbol?
Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."
Who are some of Durata Therapeutics' key competitors?
Some companies that are related to Durata Therapeutics include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), VBI Vaccines (VBIV), Anavex Life Sciences Corp. (AVXL), Mirati Therapeutics (MRTX), XOMA Corporation (XOMA), ContraFect Corporation (CFRX), Aevi Genomic Medicine (GNMX), Trillium Therapeutics (TRIL), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF), KaloBios Pharmaceuticals (KBIO), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY) and Cubist Pharmaceuticals (CBST).
How do I buy Durata Therapeutics stock?
Shares of Durata Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Durata Therapeutics' stock price today?
MarketBeat Community Rating for Durata Therapeutics (NASDAQ DRTX)MarketBeat's community ratings are surveys of what our community members think about Durata Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Durata Therapeutics stock can currently be purchased for approximately $24.16.
Consensus Ratings for Durata Therapeutics (NASDAQ:DRTX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Durata Therapeutics (NASDAQ:DRTX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Durata Therapeutics (NASDAQ:DRTX)Earnings History by Quarter for Durata Therapeutics (NASDAQ DRTX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Durata Therapeutics (NASDAQ:DRTX)
Current Year EPS Consensus Estimate: $-2.97 EPS
Next Year EPS Consensus Estimate: $-1.37 EPS
Dividend History for Durata Therapeutics (NASDAQ:DRTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Durata Therapeutics (NASDAQ:DRTX)Insider Trades by Quarter for Durata Therapeutics (NASDAQ:DRTX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/12/2014||John Patrick Shannon Jr||Insider||Buy||3,000||$13.72||$41,160.00|| |
|6/12/2014||Paul R Edick||CEO||Buy||3,000||$15.23||$45,690.00|| |
|5/12/2014||Schutter Richard De||Director||Buy||15,000||$15.57||$233,550.00|| |
|3/21/2014||Aisling Capital Iii Lp||major shareholder||Sell||100,649||$15.74||$1,584,215.26|| |
|12/3/2013||Lisa Giles||Director||Buy||1,000||$10.95||$10,950.00|| |
|5/20/2013||Paul R Edick||CEO||Buy||3,000||$7.09||$21,270.00|| |
|8/14/2012||Paul R Edick||CEO||Buy||5,000||$8.65||$43,250.00|| |
Headline Trends for Durata Therapeutics (NASDAQ:DRTX)
Latest Headlines for Durata Therapeutics (NASDAQ:DRTX)
Durata Therapeutics (DRTX) Chart for Friday, July, 21, 2017